MDWD vs ORGO
MDWD: MediWound is a biopharmaceutical developer specializing in enzymatic debridement technology for burn wound and tissue repair. ORGO: A regenerative medicine company providing advanced wound care and surgical tissue-engineered products to improve healing outcomes in patients with chronic and acute wounds.
Side-by-side fundamentals
| Metric | MDWD | ORGO | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $12.42 | $1.28 | |
| Market cap | $174M | $165M | |
| Net margin FY2025, SEC XBRL | -140.8% | +6.6% | ORGO higher |
| Gross margin | +19.2% | +76.0% | ORGO higher |
| Operating margin FY2025, SEC XBRL | -149.0% | +7.9% | ORGO higher |
| ROE FY2025, SEC XBRL | -54.7% | +12.3% | ORGO higher |
| ROA FY2025, SEC XBRL | -27.7% | +6.2% | ORGO higher |
| Debt / equity as of 2026-09-03 | 0.20 | 0.03 | ORGO lower |
| Revenue growth (YoY) as of 2026-09-03 | -24.6% | +12.2% | ORGO higher |
| Revenue CAGR (3y) SEC XBRL | -13.8% | +7.8% | ORGO higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.71 | 1.53 | |
| 1-year return as of 2026-10-08 close | -29.5% | -69.0% | MDWD higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.